Mavyret and Vosevi Will Join the Market of Oral Hep C Meds

You'll see big changes in treating hepatitis C due to the new oral antivirals, Mavyret (MAV-ih-reht) and Vosevi (voh-SEV-ee).

Mavyret (glecaprevir/pibrentasvir) will be a game changer.

It's the first hep C med that's approved to use for just 8 weeks for any type of hep C in most patients...instead of the usual 12 weeks.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote